# A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

> **NCT03679455** · PHASE2 · UNKNOWN · sponsor: **Polish Myeloma Consortium** · enrollment: 30 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Obinutuzumab 25 MG/ML

## Key facts

- **NCT ID:** NCT03679455
- **Lead sponsor:** Polish Myeloma Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-21
- **Primary completion:** 2019-04
- **Final completion:** 2022-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679455, "A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03679455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*